KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Clover Health Investments (CLOV) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Clover Health Investments (CLOV) over the last 7 years, with Q3 2025 value amounting to $512.7 million.

  • Clover Health Investments' Shares Outstanding (Weighted Average) rose 460.31% to $512.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $512.7 million, marking a year-over-year increase of 460.31%. This contributed to the annual value of $490.0 million for FY2024, which is 162.65% up from last year.
  • Clover Health Investments' Shares Outstanding (Weighted Average) amounted to $512.7 million in Q3 2025, which was up 460.31% from $509.0 million recorded in Q2 2025.
  • Clover Health Investments' 5-year Shares Outstanding (Weighted Average) high stood at $512.7 million for Q3 2025, and its period low was $376.2 million during Q1 2021.
  • For the 5-year period, Clover Health Investments' Shares Outstanding (Weighted Average) averaged around $468.9 million, with its median value being $479.8 million (2023).
  • Per our database at Business Quant, Clover Health Investments' Shares Outstanding (Weighted Average) soared by 36652.89% in 2021 and then surged by 67.64% in 2023.
  • Clover Health Investments' Shares Outstanding (Weighted Average) (Quarter) stood at $412.9 million in 2021, then increased by 15.34% to $476.2 million in 2022, then increased by 1.25% to $482.2 million in 2023, then rose by 1.63% to $490.0 million in 2024, then increased by 4.64% to $512.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $512.7 million for Q3 2025, versus $509.0 million for Q2 2025 and $497.1 million for Q1 2025.